Clinical trials: Injections
Obesity, Over-weight
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
- Conditions
- Obesity, Over-weight, Prader-Willi Syndrome
- Trial name
- NCT01818921
- Testing
- ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Zafgen, Inc.
Glabellar Lines
Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.
- Trial name
- NCT07622004
- Testing
- Botulinum Toxin Type A Injection [INI101], Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- INIBIO Co., Ltd.
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Overweight/Obesity
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
The study is being conducted to evaluate the bioequivalence between a single-dose pen and a multi-dose pen of HRS9531 injection solution.
- Trial name
- NCT06792955
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Secondary Hyperparathyroidism, End Stage Renal Disease
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
- Trial name
- NCT00053547
- Testing
- paricalcitol injection
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Abbott
Diabetes Mellitus
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI…
- Trial name
- NCT00135941
- Testing
- insulin glargine, insulin glulisine
- Where
- United States
- Volunteers
- 582 people
- Sponsor
- Sanofi
Diabetes Mellitus, Weight Loss
A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function
This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531…
- Trial name
- NCT07540754
- Testing
- HRS9531 Injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Weight Loss
Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss
The goal of this clinical trial is to determine the effect of a low carbohydrate higher protein diet, modelled after the Atkins program on weight loss, glycemic control, risk markers of cardiovascular disease and body composition…
- Trial name
- NCT07280403
- Testing
- Low Carbohydrate, Low Fat
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- INQUIS Clinical Research
Adult, Lung Cancer
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) for treatment of patients with Advanced lung cancer,while evaluating…
- Trial name
- NCT06519669
- Testing
- GT201 injection
- Where
- 2 sites in China
- Volunteers
- 2 people
- Sponsor
- Grit Biotechnology
Diabetes Mellitus
Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration
The primary objective is to assess the speed of absorption of BIOD-123 and BIOD-125 and compare them to Humalog.
- Trial name
- NCT01908894
- Testing
- BIOD-123, BIOD-125, Humalog
- Volunteers
- 12 people
- Sponsor
- Biodel
Osteoarthritis of the Knee
Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation
The study will evaluate Apitox, pure honeybee venom as a treatment for pain and inflammation of osteoarthritis of the knee.
- Trial name
- HBV (NCT00949754)
- Testing
- honeybee venom (Apitoxin (Korea) Apitox (USA))
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Apimeds, Inc.
Autoimmune Disease
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
This study is designed to evaluate the safety, tolerability, PK and PD of GenSci136 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
- Trial name
- NCT07366866
- Testing
- GenSci136
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Pregnancy
Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood
This study will evaluate the levels of hydroxyprogesterone caproate and it's metabolites in blood throughout pregnancy There will be 3 cohorts of subjects Cohort 1 (6 subjects) will have daily blood draws in the morning at…
- Trial name
- NCT01899846
- Testing
- Hydroxyprogesterone caproate 250 mg/ml
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Lumara Health, Inc.
Advanced Solid Tumor, Lung Squamous Cell Carcinoma
JMT106 Injection in the Treatment of Advanced Solid Tumors
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT07275073
- Testing
- JMT106 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Solid Tumors, Adult
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up…
- Trial name
- NCT05430373
- Testing
- GT101
- Where
- 5 sites in China
- Volunteers
- 31 people
- Sponsor
- Grit Biotechnology
Peripheral Arterial Occlusive Disease
Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
The primary objective is to evaluate safety and tolerability of single and repeated administrations of escalating doses of NV1FGF administered intramuscularly in patients with severe Peripheral Artery Occlusive Disease (PAOD)…
- Trial name
- NCT01157156
- Testing
- XRP0038 (NV1FGF)
- Where
- 2 sites in United States, Finland
- Volunteers
- 51 people
- Sponsor
- Sanofi
Multifollicular Stimulation
An Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to In-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)
This is a prospective, observational study in women using Gonal-F filled-by-mass (FbM) in ovarian hyperstimulation as part of their in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment at infertility…
- Trial name
- NCT01075854
- Testing
- Gonal-F (Follitropin alfa)
- Where
- South Korea
- Volunteers
- 1,539 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
This trial was designed to evaluate the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) in subjects with TQB3912 tablets combined with fulvestrant injection and TQB3616 capsules for locally advanced or…
- Trial name
- NCT06851442
- Testing
- TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
- Where
- 17 sites in China
- Volunteers
- 8 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
- Trial name
- NCT05864105
- Testing
- PM8002, FOLFOX regimen
- Where
- 9 sites in China
- Volunteers
- 35 people
- Sponsor
- Biotheus Inc.
Post-operative Nausea and Vomiting (PONV)
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,
- Trial name
- NCT06543966
- Testing
- Aprepitant Injection
- Volunteers
- 486 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.